Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | LSS | P48449 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.32 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.31 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1787869 | 1.00 | HTR2C (0.36) | HTR2CESR2SPHK1CYP2C9ESR1 | |
| SCHEMBL1787895 | 1.00 | HTR2C (0.36) | HTR2CESR2SPHK1CYP2C9ESR1 | |
| SCHEMBL16213455 | 0.84 | ESR2 (0.42) | ESR2SPHK1CYP2C9ESR1CYP3A4 | |
| SCHEMBL12603843 | 0.82 | SPHK1 (0.41) | HTR2CESR2SPHK1CYP2C9 | |
| SCHEMBL15437191 | 0.82 | HTR2C (0.36) | HTR2CESR2SPHK1CYP2C9ESR1 | |
| SCHEMBL1780216 | 0.82 | ESR2 (0.42) | HTR2CESR2SPHK1CYP2C9ESR1 | |
| SCHEMBL12603782 | 0.82 | SPHK1 (0.41) | HTR2CESR2SPHK1CYP2C9 | |
| SCHEMBL15437190 | 0.82 | HTR2C (0.36) | HTR2CESR2SPHK1CYP2C9ESR1 | |
| SCHEMBL1781540 | 0.82 | ESR2 (0.42) | HTR2CESR2SPHK1CYP2C9ESR1 | |
| SCHEMBL12603781 | 0.82 | SPHK1 (0.41) | HTR2CESR2SPHK1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197551-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2016-12-28 | — | — | EP | disclosed |
| US-8455638-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2011-05-19 | — | — | US | disclosed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | GUCY1B1, GUCY1A2, GUCY1A1 | HTR2C 2306/4885ESR2 823/4885SPHK1 827/4885 |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B1, GUCY1A2, GUCY1A1 | HTR2C 2306/4885ESR2 823/4885SPHK1 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.